Teva Pharmaceutical Industries Limited (TEVA)
USD 21.2
(1.53%)
USD 21.2
(1.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 35.35 Billion USD | 0.11% |
| 2022 | 35.31 Billion USD | -3.04% |
| 2021 | 36.42 Billion USD | -7.98% |
| 2020 | 39.57 Billion USD | -6.67% |
| 2019 | 42.4 Billion USD | -5.53% |
| 2018 | 44.88 Billion USD | -13.46% |
| 2017 | 51.87 Billion USD | -10.41% |
| 2016 | 57.89 Billion USD | 137.96% |
| 2015 | 24.33 Billion USD | 5.49% |
| 2014 | 23.06 Billion USD | -7.27% |
| 2013 | 24.87 Billion USD | -10.35% |
| 2012 | 27.74 Billion USD | -0.21% |
| 2011 | 27.79 Billion USD | 63.04% |
| 2010 | 17.05 Billion USD | 17.17% |
| 2009 | 14.55 Billion USD | -12.05% |
| 2008 | 16.54 Billion USD | 71.4% |
| 2007 | 9.65 Billion USD | 3.85% |
| 2006 | 9.29 Billion USD | 114.29% |
| 2005 | 4.33 Billion USD | 2.48% |
| 2004 | 4.23 Billion USD | 61.55% |
| 2003 | 2.61 Billion USD | -6.18% |
| 2002 | 2.79 Billion USD | 34.43% |
| 2001 | 2.07 Billion USD | 22.01% |
| 2000 | 1.7 Billion USD | 75.22% |
| 1999 | 971.71 Million USD | 25.16% |
| 1998 | 776.4 Million USD | 34.89% |
| 1997 | 575.6 Million USD | -18.49% |
| 1996 | 706.2 Million USD | 52.3% |
| 1995 | 463.7 Million USD | 39.0% |
| 1994 | 333.6 Million USD | 13.08% |
| 1993 | 295 Million USD | 32.94% |
| 1992 | 221.9 Million USD | 14.56% |
| 1991 | 193.7 Million USD | -6.96% |
| 1990 | 208.2 Million USD | 24.45% |
| 1989 | 167.3 Million USD | 12.28% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 35.23 Billion USD | -0.35% |
| 2024 Q2 | 34.77 Billion USD | -1.29% |
| 2023 Q1 | 34.84 Billion USD | -1.33% |
| 2023 Q3 | 34.57 Billion USD | -2.29% |
| 2023 Q2 | 35.38 Billion USD | 1.56% |
| 2023 Q4 | 35.35 Billion USD | 2.24% |
| 2023 FY | 35.35 Billion USD | 0.11% |
| 2022 Q4 | 35.31 Billion USD | 1.67% |
| 2022 Q1 | 36.79 Billion USD | 1.04% |
| 2022 Q2 | 36.1 Billion USD | -1.89% |
| 2022 FY | 35.31 Billion USD | -3.04% |
| 2022 Q3 | 34.73 Billion USD | -3.79% |
| 2021 Q2 | 37.88 Billion USD | -0.38% |
| 2021 Q1 | 38.02 Billion USD | -3.92% |
| 2021 Q4 | 36.42 Billion USD | 0.06% |
| 2021 Q3 | 36.4 Billion USD | -3.92% |
| 2021 FY | 36.42 Billion USD | -7.98% |
| 2020 Q2 | 40.16 Billion USD | -1.41% |
| 2020 Q3 | 39.14 Billion USD | -2.54% |
| 2020 Q1 | 40.74 Billion USD | -3.93% |
| 2020 Q4 | 39.57 Billion USD | 1.11% |
| 2020 FY | 39.57 Billion USD | -6.67% |
| 2019 Q4 | 42.4 Billion USD | 0.2% |
| 2019 Q2 | 44.17 Billion USD | 0.32% |
| 2019 FY | 42.4 Billion USD | -5.53% |
| 2019 Q1 | 44.03 Billion USD | -1.91% |
| 2019 Q3 | 42.32 Billion USD | -4.19% |
| 2018 Q2 | 47.66 Billion USD | -2.89% |
| 2018 Q1 | 49.07 Billion USD | -5.38% |
| 2018 FY | 44.88 Billion USD | -13.46% |
| 2018 Q4 | 44.88 Billion USD | -2.26% |
| 2018 Q3 | 45.92 Billion USD | -3.64% |
| 2017 Q1 | 55.53 Billion USD | -4.09% |
| 2017 Q3 | 55.78 Billion USD | -1.69% |
| 2017 FY | 51.87 Billion USD | -10.41% |
| 2017 Q2 | 56.74 Billion USD | 2.19% |
| 2017 Q4 | 51.87 Billion USD | -7.02% |
| 2016 Q1 | 24.53 Billion USD | 0.84% |
| 2016 FY | 57.89 Billion USD | 137.96% |
| 2016 Q3 | 61.71 Billion USD | 138.32% |
| 2016 Q4 | 57.89 Billion USD | -6.19% |
| 2016 Q2 | 25.89 Billion USD | 5.55% |
| 2015 Q3 | 25.72 Billion USD | -5.72% |
| 2015 FY | 24.33 Billion USD | 5.49% |
| 2015 Q2 | 27.28 Billion USD | 12.41% |
| 2015 Q1 | 24.27 Billion USD | 5.24% |
| 2015 Q4 | 24.33 Billion USD | -5.42% |
| 2014 Q2 | 23.14 Billion USD | -3.0% |
| 2014 Q1 | 23.86 Billion USD | -4.06% |
| 2014 Q4 | 23.06 Billion USD | 0.55% |
| 2014 FY | 23.06 Billion USD | -7.27% |
| 2014 Q3 | 22.93 Billion USD | -0.89% |
| 2013 Q1 | 25.25 Billion USD | -8.96% |
| 2013 Q2 | 25.89 Billion USD | 2.53% |
| 2013 FY | 24.87 Billion USD | -10.35% |
| 2013 Q4 | 24.87 Billion USD | -2.32% |
| 2013 Q3 | 25.46 Billion USD | -1.66% |
| 2012 FY | 27.74 Billion USD | -0.21% |
| 2012 Q1 | 27.27 Billion USD | -1.9% |
| 2012 Q4 | 27.74 Billion USD | 4.66% |
| 2012 Q2 | 25.98 Billion USD | -4.7% |
| 2012 Q3 | 26.5 Billion USD | 2.0% |
| 2011 Q2 | 16.4 Billion USD | 1.79% |
| 2011 Q1 | 16.12 Billion USD | -0.19% |
| 2011 Q4 | 27.79 Billion USD | 51.58% |
| 2011 Q3 | 18.33 Billion USD | 11.76% |
| 2011 FY | 27.79 Billion USD | 63.04% |
| 2010 Q1 | 14.36 Billion USD | -1.26% |
| 2010 Q4 | 16.15 Billion USD | -6.81% |
| 2010 Q3 | 17.33 Billion USD | 9.53% |
| 2010 Q2 | 15.82 Billion USD | 10.12% |
| 2010 FY | 17.05 Billion USD | 17.17% |
| 2009 FY | 14.55 Billion USD | -12.05% |
| 2009 Q2 | 14.4 Billion USD | -10.59% |
| 2009 Q3 | 13.99 Billion USD | -2.83% |
| 2009 Q4 | 14.55 Billion USD | 3.98% |
| 2009 Q1 | 16.1 Billion USD | -2.65% |
| 2008 Q2 | 9.9 Billion USD | -2.88% |
| 2008 Q1 | 10.19 Billion USD | 5.66% |
| 2008 FY | 16.54 Billion USD | 71.4% |
| 2008 Q3 | 10.09 Billion USD | 1.88% |
| 2008 Q4 | 16.54 Billion USD | 63.96% |
| 2007 Q1 | 9.6 Billion USD | 3.32% |
| 2007 Q2 | 9.65 Billion USD | 0.5% |
| 2007 Q3 | 9.53 Billion USD | -1.17% |
| 2007 Q4 | 9.65 Billion USD | 1.2% |
| 2007 FY | 9.65 Billion USD | 3.85% |
| 2006 FY | 9.29 Billion USD | 114.29% |
| 2006 Q3 | 9.39 Billion USD | -0.45% |
| 2006 Q4 | 9.29 Billion USD | -1.04% |
| 2006 Q1 | 9.12 Billion USD | 110.37% |
| 2006 Q2 | 9.43 Billion USD | 3.4% |
| 2005 Q2 | 4.11 Billion USD | -2.2% |
| 2005 Q1 | 4.2 Billion USD | -0.57% |
| 2005 FY | 4.33 Billion USD | 2.48% |
| 2005 Q4 | 4.33 Billion USD | 6.07% |
| 2005 Q3 | 4.08 Billion USD | -0.64% |
| 2004 Q4 | 4.23 Billion USD | 6.01% |
| 2004 Q3 | 3.99 Billion USD | -6.29% |
| 2004 Q2 | 4.26 Billion USD | 0.03% |
| 2004 Q1 | 4.25 Billion USD | 62.57% |
| 2004 FY | 4.23 Billion USD | 61.55% |
| 2003 Q4 | 2.61 Billion USD | -13.61% |
| 2003 Q3 | 3.03 Billion USD | 0.31% |
| 2003 Q2 | 3.02 Billion USD | 4.75% |
| 2003 Q1 | 2.88 Billion USD | 3.36% |
| 2003 FY | 2.61 Billion USD | -6.18% |
| 2002 Q3 | 2.24 Billion USD | 1.87% |
| 2002 Q2 | 2.19 Billion USD | 6.56% |
| 2002 Q1 | 2.06 Billion USD | -0.63% |
| 2002 FY | 2.79 Billion USD | 34.43% |
| 2002 Q4 | 2.79 Billion USD | 24.62% |
| 2001 Q4 | 2.07 Billion USD | 0.25% |
| 2001 FY | 2.07 Billion USD | 22.01% |
| 2001 Q1 | 1.62 Billion USD | -4.81% |
| 2001 Q2 | 1.59 Billion USD | -1.77% |
| 2001 Q3 | 2.07 Billion USD | 30.15% |
| 2000 Q1 | 971.2 Million USD | -0.05% |
| 2000 FY | 1.7 Billion USD | 75.22% |
| 2000 Q2 | 1.3 Billion USD | 34.41% |
| 2000 Q4 | 1.7 Billion USD | 34.04% |
| 2000 Q3 | 1.27 Billion USD | -2.69% |
| 1999 Q2 | 739.1 Million USD | -0.77% |
| 1999 Q3 | 1.03 Billion USD | 40.36% |
| 1999 Q4 | 971.71 Million USD | -6.33% |
| 1999 FY | 971.71 Million USD | 25.16% |
| 1999 Q1 | 744.8 Million USD | -4.07% |
| 1998 Q3 | 759.2 Million USD | 18.07% |
| 1998 Q2 | 643 Million USD | 19.41% |
| 1998 Q1 | 538.5 Million USD | -6.45% |
| 1998 Q4 | 776.4 Million USD | 2.27% |
| 1998 FY | 776.4 Million USD | 34.89% |
| 1997 Q4 | 575.6 Million USD | 0.0% |
| 1997 FY | 575.6 Million USD | -18.49% |
| 1996 Q4 | 706.2 Million USD | 0.0% |
| 1996 FY | 706.2 Million USD | 52.3% |
| 1995 FY | 463.7 Million USD | 39.0% |
| 1995 Q4 | 463.7 Million USD | 0.0% |
| 1994 FY | 333.6 Million USD | 13.08% |
| 1994 Q4 | 333.6 Million USD | 0.0% |
| 1993 FY | 295 Million USD | 32.94% |
| 1993 Q4 | 295 Million USD | 0.0% |
| 1992 Q4 | 221.9 Million USD | 0.0% |
| 1992 FY | 221.9 Million USD | 14.56% |
| 1991 FY | 193.7 Million USD | -6.96% |
| 1991 Q4 | 193.7 Million USD | 0.0% |
| 1990 Q4 | 208.2 Million USD | 0.0% |
| 1990 FY | 208.2 Million USD | 24.45% |
| 1989 FY | 167.3 Million USD | 12.28% |
| 1989 Q4 | 167.3 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 3.45 Billion USD | -923.965% |
| Bausch Health Companies Inc. | 27.43 Billion USD | -28.875% |
| Catalent, Inc. | 6.14 Billion USD | -474.939% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -2881.866% |
| Elanco Animal Health Incorporated | 8.13 Billion USD | -334.365% |
| Perrigo Company plc | 6.04 Billion USD | -485.198% |
| Zoetis Inc. | 9.29 Billion USD | -280.344% |